Freedom: Market Reacts Cautiously to Novo Nordisk’s New Market Entry

Novo Nordisk (NOVOb) has launched sales of the tablet version of its weight-loss drug Wegovy in the UAE. This marks the first market outside the U.S. where the company is introducing this new form of its flagship product. According to Freedom analyst Natalya Milchakova, the international expansion is intended to help the Danish manufacturer offset the intensifying competition in the U.S. weight-loss drug market.

Novo Nordisk is one of the world’s largest pharmaceutical companies, specializing in diabetes and obesity treatments. Wegovy has been a key growth driver for the company’s business in recent years.

Natalya Milchakova notes that the launch of the tablet version of Wegovy in the UAE is driven by Novo Nordisk’s desire to strengthen its position outside the U.S., where competition in the weight-loss segment has become notably fierce. Eli Lilly remains one of the main rivals, having previously brought its own weight-loss tablet to market and garnered significant consumer interest.

Freedom highlights that markets outside the U.S. are still less competitive, creating additional opportunities for Novo Nordisk to boost sales. The launch of Wegovy in its new form could expand the patient base, attracting those who prefer tablets over injections.

Despite the strategic importance of the event, investors reacted cautiously: Novo Nordisk’s shares slightly declined in the U.S. pre-market trading. The analyst believes the market is waiting for the first financial results to confirm that international sales can compensate for the slowing growth in the U.S. market.

Freedom believes that the future performance of Novo Nordisk’s stock will depend on how quickly the company can increase Wegovy sales outside the U.S. and strengthen its position in the global weight-loss drug market against Eli Lilly.

Not an individual investment recommendation.